Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2018 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections

BOSTON, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
November 27, 2018 07:30 ET | Source: Cytokinetics, Incorporated

Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in FORTITUDE-ALS (Functional Outcomes in...
November 27, 2018 07:00 ET | Source: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to...
November 27, 2018 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Expands Loan Agreement with Silicon Valley Bank Providing Additional Growth Capital Related to AXS-12 Product Candidate

NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
November 27, 2018 07:00 ET | Source: BeyondSpring, Inc.

Plinabulin Newly Granted Patent Covering Method of Use in Prevention of Neutropenia

NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the...
November 27, 2018 07:00 ET | Source: Arsanis, Inc.

Arsanis and X4 Pharmaceuticals Agree to Merger

– Merger Expected to Create NASDAQ-listed, Late-stage Biopharmaceutical Company Focused on Rare Diseases and Cancer – – Phase 3 Clinical Trial for X4P-001, a Novel CXCR4 Antagonist, Anticipated to...
November 27, 2018 06:00 ET | Source: CytoDyn Inc.

CytoDyn to Present at Two Investment Conferences in December

VANCOUVER, Washington, Nov. 27, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic...
November 27, 2018 06:00 ET | Source: Invivoscribe, Inc.

Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib

SAN DIEGO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submissions of the LeukoStrat® CDx FLT3 Mutation Assay to...
November 27, 2018 01:00 ET | Source: Sensorion

Sensorion Announces Completion of Patient Enrollment and Dosing in Seliforant Phase 2a Study

MONTPELLIER, France, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a clinical-stage biopharmaceutical company specializing in the treatment of inner ear diseases, announced...
November 26, 2018 17:30 ET | Source: Huawei Technologies

Huawei Launches the Evolution Strategy for 5G-oriented Wireless Target Network

London, Nov. 26, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- At Global Mobile Broadband Forum 2018, Huawei released the "All Bands Go to 5G" strategy for the evolution towards a 5G-oriented...